Clearside Biomedical (NASDAQ:CLSD) Issues Quarterly Earnings Results

Clearside Biomedical (NASDAQ:CLSDGet Rating) issued its earnings results on Wednesday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.10), MarketWatch Earnings reports. Clearside Biomedical had a return on equity of 0.33% and a net margin of 0.28%. During the same quarter in the prior year, the firm earned ($0.13) EPS.

CLSD stock traded up $0.05 during trading on Friday, reaching $1.41. The company had a trading volume of 178,252 shares, compared to its average volume of 300,645. The firm has a 50-day simple moving average of $1.99 and a 200-day simple moving average of $2.59. Clearside Biomedical has a twelve month low of $1.30 and a twelve month high of $7.73.

A number of hedge funds have recently added to or reduced their stakes in CLSD. Mackenzie Financial Corp acquired a new stake in Clearside Biomedical in the 1st quarter worth approximately $27,000. Citigroup Inc. raised its position in Clearside Biomedical by 190.2% during the 4th quarter. Citigroup Inc. now owns 9,863 shares of the company’s stock worth $27,000 after buying an additional 6,464 shares during the last quarter. Walleye Trading LLC purchased a new position in Clearside Biomedical during the 4th quarter worth approximately $32,000. BNP Paribas Arbitrage SA raised its position in Clearside Biomedical by 1,462,200.0% during the 4th quarter. BNP Paribas Arbitrage SA now owns 14,623 shares of the company’s stock worth $40,000 after buying an additional 14,622 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in Clearside Biomedical during the 4th quarter worth approximately $40,000. Institutional investors own 44.71% of the company’s stock.

Several brokerages have issued reports on CLSD. StockNews.com began coverage on shares of Clearside Biomedical in a report on Thursday, March 31st. They set a “hold” rating on the stock. TheStreet cut shares of Clearside Biomedical from a “c” rating to a “d+” rating in a report on Wednesday. Zacks Investment Research cut shares of Clearside Biomedical from a “buy” rating to a “hold” rating in a report on Monday, May 2nd. JMP Securities lowered their price target on shares of Clearside Biomedical from $11.00 to $10.00 and set a “market outperform” rating on the stock in a report on Friday, March 11th. Finally, Wedbush restated an “outperform” rating and issued a $9.00 price target on shares of Clearside Biomedical in a report on Friday, March 11th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Clearside Biomedical has a consensus rating of “Buy” and an average price target of $9.25.

About Clearside Biomedical (Get Rating)

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.

See Also

Earnings History for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.